Qiagen NV  

(Public, FRA:QIA)   Watch this stock  
Find more results for QIA
31.01
-0.49 (-1.56%)
Jun 23 - Close
FRA real-time data - Disclaimer
Currency in EUR
Range 30.98 - 31.19
52 week 23.46 - 79.13
Open 31.06
Vol. 966.00
Mkt cap 7.12B
P/E 96.04
Div/yield 1.01
EPS 0.32
Shares 227.66M
Beta     -
Inst. own     -
Jul 27, 2017
Q2 2017 Qiagen NV Earnings Release - 10:00PM GMT+2 - Add to calendar
Jun 23, 2017
Qiagen NV at Deutsche Bank dbAccess Berlin Conference
Jun 22, 2017
Qiagen NV at JPMorgan European Healthcare Conference
Jun 21, 2017
Qiagen NV Annual Shareholders Meeting - Webcast
Jun 14, 2017
Qiagen NV at Goldman Sachs Global Healthcare Conference - Webcast
Jun 1, 2017
Qiagen NV at Societe Generale CIB Nice Conference
May 23, 2017
Qiagen NV at UBS Global Healthcare Conference - Webcast
May 3, 2017
Qiagen NV at Deutsche Bank Health Care Conference - Webcast
May 3, 2017
Q1 2017 Qiagen NV Earnings Call - Webcast
May 2, 2017
Q1 2017 Qiagen NV Earnings Release
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 5.74% 6.00%
Operating margin 7.72% 7.39%
EBITD margin - 23.31%
Return on average assets 1.69% 1.89%
Return on average equity 2.81% 3.11%
Employees 4,600 -
CDP Score - -

Address

Hulsterweg 82
VENLO, 5912 PL
Netherlands
+31-77-3556600 (Phone)
+31-77-3208409 (Fax)

Website links

Description

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Officers and directors

Werner Brandt Independent Chairman of the Supervisory Board
Age: 63
Peer M. Schatz Chief Executive Officer, Managing Director
Age: 50
Roland Sackers Chief Financial Officer, Managing Director
Age: 47
Thomas Schweins Senior Vice President - Human Resources, Strategy & Marketing Services
Thierry Bernard Senior Vice President - Molecular Diagnostics Business Area
Brad J. Crutchfield Senior Vice President - Life Sciences Business Area
Age: 53
Laura Furmanski Ph.D. Senior Vice President - Bioinformatics Business Area
Douglas Liu Senior Vice President - Global Operations
Manuel O. Mendez Senior Vice President - Global Commercial Operations
Age: 43
Stephane Bancel Independent Supervisory Director
Age: 44